Clinical Trials And DevelopmentKIO-301 is being developed to restore lost vision in patients with retinal diseases, representing a promising lead asset for Kiora Pharmaceuticals.
Financial PerformanceKiora Pharmaceuticals reported $24.1M in cash, providing runway into late 2027.
Partnership And LicensingKiora Pharmaceuticals announced a license deal, selling commercial rights for KIO-301 in Asia to Senju Pharmaceutical Co., receiving an immediate $1.25M option fee and potential deal value of $110M.